XORTX Completes Manufacturing of Clinical Drug Supply
Key Highlights
- ➤XORTX (XRTX) completes manufacturing and packaging of XRX-OXY-102 clinical supply
- ➤XRX-OXY-102 Part 1 will characterize XORLO steady-state pharmacokinetics
- ➤XRX-OXY-102 Part 2 will evaluate XORLO therapeutic equivalence versus allopurinol
- ➤Manufacturing validation data will support planned Health Canada CTA filing
- ➤Study data is intended to support planned FDA NDA submission
Expert Statements
Allen Davidoff, Co-CEO of XORTX Therapeutics Inc.
“At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.”
Mika Grasso, Co-CEO of XORTX Therapeutics Inc.
“At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.”
● Clinical Drug Supply and Packaging completed in preparation for the XRX-OXY-102 Clinical Study ●
CALGARY, Alberta, Nov. 16, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that manufacturing and packaging of clinical drug supply for the XRX-OXY-102 clinical trial has been completed. Production of XORTX’s clinical drug supply is based on proprietary synthetic pathway for production of high yield pure oxypurinol, then formulated using our proprietary and patented formulation of this drug. This process to produce the formulation and tablet format the Company aims to advance through marketing approval is a key step forward for the XRx-026 program for the treatment of gout.
Get started
Create a free account to read the full story.
